Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 movers: Carnival buoyed by Q4 results, drugmakers higher

Thu, 19th Dec 2013 14:47

Cruise operator Carnival surged into the top spot on the FTSE 100 risers list on Thursday after reporting a smaller-than-expected decline in net revenue yields in the fourth quarter. Net revenue yields in constant dollars fell by 2.1 per cent year-on-year, better than the company's guidance given in September of a 3-4 per cent fall.AstraZeneca was higher after spending up to $4.1bn to buy out Bristol-Myers Squibb's stake in their diabetes joint venture, giving the Anglo-Swedish company full ownership of intellectual property and global rights for a large portfolio of products.Fellow pharma group GlaxoSmithKline (GSK) also advanced after US regulators approved Anoro Ellipta, its treatment for chronic obstructive pulmonary disease. Upside however was limited on the news that Denmark has approved the sale of a generic rival to GSK's biggest product, Advair.Precious metal miners Fresnillo and Randgold Resources were among the few fallers on the FTSE 100, with the stocks tracking heavy falls in gold and silver prices in afternoon trade.Glencore Xstrata was also lower. The company announced this morning that it has bought up a further 14.5% stake in Congolese copper and cobalt producer Mutanda Mining for $430m cash, taking its controlling stake to 69%.G4S was in the red after the government referred the security group to the Serious Fraud Office following a review of outsourcing contracts due to suspected over-charging.FTSE 100 - RisersCarnival (CCL) 2,318.00p +5.75%Petrofac Ltd. (PFC) 1,131.00p +3.86%William Hill (WMH) 387.70p +3.22%Standard Life (SL.) 350.10p +2.88%British Land Co (BLND) 615.50p +2.75%Hargreaves Lansdown (HL.) 1,305.00p +2.68%Associated British Foods (ABF) 2,391.00p +2.66%Land Securities Group (LAND) 951.00p +2.48%Smith & Nephew (SN.) 855.00p +2.27%Sage Group (SGE) 394.00p +2.26%FTSE 100 - FallersFresnillo (FRES) 701.00p -3.58%Randgold Resources Ltd. (RRS) 3,802.00p -2.91%G4S (GFS) 247.90p -2.29%Anglo American (AAL) 1,265.50p -0.94%HSBC Holdings (HSBA) 642.50p -0.89%Glencore Xstrata (GLEN) 305.20p -0.51%Sainsbury (J) (SBRY) 363.50p -0.44%Johnson Matthey (JMAT) 3,205.00p -0.22%BC
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.